By SPC Staff
Results from a phase 2b trial indicate that the investigational drug TAK-279 (Takeda) significantly improved clearance of skin lesions for patients with moderate to severe plaque psoriasis, the company announced at the 2023 American Academy of Dermatology Annual Meeting, held in New Orleans. The medication is a tyrosine kinase 2 inhibitor taken orally once daily.
During the double-blind trial, 259 patients were randomized into five groups to receive one of four doses of TAK-279 (2,